This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03142152
Recruitment Status : Recruiting
First Posted : May 5, 2017
Last Update Posted : February 28, 2024
Sponsor:
Information provided by (Responsible Party):
Cardiac Dimensions Pty Ltd ( Cardiac Dimensions, Inc. )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).

Condition or disease Intervention/treatment Phase
Functional Mitral Regurgitation Heart Failure Mitral Valve Insufficiency Heart Diseases Cardiovascular Diseases Heart Valve Diseases Device: Carillon Mitral Contour System Other: Guideline Directed Heart Failure Medication Not Applicable

Detailed Description:

A total of 300 subjects will be randomized at up to 75 investigational sites in the United States, Canada, Europe and Australia. Subjects will be randomized into one of two study groups using a 1:1 (Intervention : Control) ratio.

Study subjects who are eligible for this clinical study will undergo a transthoracic echocardiographic examination prior to randomization to evaluate the inclusion criteria associated with the severity of mitral regurgitation. A coronary angiogram will be performed to evaluate the coronary artery anatomy and a venogram to assess the suitability of the coronary sinus/great cardiac vein (CS/GCV) for placement of the Carillon implant. If the subject meets the anatomic requirements for device placement, the subject will be randomized. Subjects who meet all eligibility criteria will be randomized into one of two study groups (Intervention or Control).

Subjects randomized to the Intervention group will undergo the Carillon implant procedure.

Subjects randomized to the Control group will experience an index procedure similar to the Intervention group (without device placement) to ensure they will not be able to deduce the group assignment based on the type of intervention or time associated with the procedure.

After the study subjects are discharged, the subjects' primary care specialists (cardiologist/heart failure physician) and clinical investigation site staff will coordinate follow-up evaluations. Subjects will be evaluated at one (1), six (6), twelve (12), eighteen (18) and twenty-four (24) months post-randomization, to assess long-term safety, and functional and clinical status.

After the 24-month evaluation, all subjects will be unblinded. All Intervention and Control subjects will be followed with an abbreviated annual contact and echocardiogram for an additional three (3) years, for a total of five (5) years.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Assessment of the Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild Functional Mitral Regurgitation
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : December 31, 2026
Estimated Study Completion Date : December 31, 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Intervention Group
Carillon Mitral Contour System and Guideline Directed Heart Failure Medication
 Device: Carillon Mitral Contour System
The Carillon implant is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
Other Names:
  • Carillon
  • Percutaneous mitral valve repair

Other: Guideline Directed Heart Failure Medication
Heart failure medication per ACC/AHA guidelines
Active Comparator: Control Group
Guideline Directed Heart Failure Medication
 Other: Guideline Directed Heart Failure Medication
Heart failure medication per ACC/AHA guidelines


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Primary Safety Objective - Freedom from Major Adverse Events [ Time Frame: 12 months ]
    Freedom from a composite of major adverse events (defined as Device Embolization, Vessel Erosion, Cardiac Perforation, and occurrence of cardiac surgery or percutaneous coronary intervention) in the Intervention group is greater than performance goal of 90%.

  2. Primary Efficacy Objective 1 - Hierarchical Clinical Composite [ Time Frame: 24 months ]
    To demonstrate that the Carillon Mitral Contour System (Intervention) group is superior to the Control group on the hierarchical composite endpoint of death, transplant or LVAD, percutaneous or surgical mitral valve intervention, heart failure hospitalization, Improvement in KCCQ, and improvement in six-minute walk distance at 24 months (analyzed when the last subject completes 12 months of follow-up.)


Secondary Outcome Measures :
  1. Secondary Efficacy Objective 1- Regurgitant Volume [ Time Frame: 12 months ]
    To compare regurgitant volume change relative to control from baseline through 12 months of follow up

  2. Secondary Efficacy Objective 2 - Change in LV End-diastolic Volume [ Time Frame: 12 months ]
    To demonstrate an improvement from baseline in the parameter left ventricular end-diastolic volume (LVEDV) associated with the Carillon Mitral Contour System (Intervention group) relative to the Control group.

  3. Secondary Efficacy Objective 3 - Change in LV End-Systolic Volume [ Time Frame: 12 months ]
    To demonstrate an improvement from baseline in the parameter left ventricular end-systolic volume (LVESV) associated with the Carillon Mitral Contour System (Intervention group) relative to the Control group.

  4. Secondary Efficacy Objective 4 - Change in 6 Minute Walk Distance [ Time Frame: 12 months ]
    To demonstrate a significantly greater improvement from baseline in six-minute walk distance associated with the Carillon Mitral Contour System (Intervention group) relative to the Control group.

  5. Secondary Efficacy Objective 5 - Change in KCCQ [ Time Frame: 12 months ]
    To demonstrate the improvement from baseline in the overall summary score of the Kansas City Cardiomyopathy Questionnaire (KCCQ) associated with the Carillon Mitral Contour System (Intervention group) relative to the Control group.

  6. Secondary Efficacy Objective 6 - Change in NYHA Classification [ Time Frame: 12 months ]
    To demonstrate the improvement in the proportion of patients who improve by at least one NYHA class from baseline associated with the Carillon Mitral Contour System (Intervention group) relative to the Control group.

  7. Secondary Efficacy Objective 7 - Percent days lost due to HFH or CV death [ Time Frame: 12 months of follow-up, and any available data up to 24 months ]
    To compare percent days lost due to HFH and CV death, relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months.

  8. Secondary Efficacy Objective 8 - Incidence of alternative therapy and all-cause mortality [ Time Frame: 12 months of follow-up, and any available data up to 24 months ]
    To compare the incidence of need for alternative therapy and all-cause mortality (superiority test if HR < 1), relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months

  9. Secondary Efficacy Objective 9 - Total number of HFH [ Time Frame: 12 months of follow-up, and any available data up to 24 months ]
    To compare total number of HFH, relative to Control, analyzed when the last subject completes 12 months of follow-up and use all available data up to 24 months

  10. Secondary Safety Objective - Freedom from peri-procedural Major Adverse Events [ Time Frame: 30 days or hospital discharge date, whichever is longer ]
    Freedom from a composite of major adverse events (defined as Death, Myocardial Infarction, Device Embolization, Vessel Erosion, Cardiac Perforation, and occurrence of cardiac surgery or percutaneous coronary intervention) in the Intervention group is greater than 80%.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of ischemic or non-ischemic cardiomyopathy
  2. Symptomatic functional (secondary) mitral regurgitation of at least 1+ (Mild) severity Note: 4+ can only be included if multidisciplinary site assessment (including a surgeon) determines that surgery is not necessary within the 1-year follow-up period for this study.
  3. NYHA Class II, III, or IV
  4. Six Minute Walk distance ≥ 100 meters and ≤ 600 meters
  5. Left Ventricular Ejection Fraction ≤ 50%
  6. LVEDD ≥ 57 mm and LVESD ≤ 75 mm
  7. Corrected BNP of ≥ 300 pg/ml, or corrected NT-proBNP ≥ 1200 pg/ml, or one or more heart failure hospitalizations within six months prior to consent
  8. Guideline directed heart failure medication regimen.

Exclusion Criteria:

  1. Pre-existing device (e.g., pacing lead) in coronary sinus (CS) / great cardiac vein (GCV) or Class I indication for cardiac resynchronization therapy (CRT)
  2. Presence of a mechanical or bio-prosthetic mitral valve or, mitral valve annuloplasty, or leaflet repair device
  3. Significant organic mitral valve pathology (e.g., moderate or severe myxomatous degeneration, with or without mitral leaflet prolapse, rheumatic disease, full or partial chordal rupture), as assessed by the Imaging Core Laboratory
  4. Severe tricuspid regurgitation associated with right ventricular dysfunction and enlargement, as assessed by the Imaging Core Laboratory
  5. Severe mitral annular calcification
  6. Severe aortic stenosis
  7. Expected to require any cardiac surgery, including surgery for coronary artery disease (CAD) or valve disease within one (1) year

  8. Chronic, severe, medical conditions or pathology, other than heart failure, that will prevent likely survival beyond twelve (12) months or any other medical condition that, in the judgment of the Investigator, makes the patient a poor candidate for this study

    • An entire list of eligibility is available in the clinical investigational plan
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03142152


Contacts
Layout table for location contacts
Contact: Angie Swenson (425) 605-5900 aswenson@cardiacdimensions.com

Locations
Show Show 62 study locations
Sponsors and Collaborators
Cardiac Dimensions, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Samir Kapadia, MD The Cleveland Clinic
Principal Investigator: Randall Starling, MD The Cleveland Clinic
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Cardiac Dimensions, Inc.
ClinicalTrials.gov Identifier: NCT03142152    
Other Study ID Numbers: CVP 1670-01
First Posted: May 5, 2017    Key Record Dates
Last Update Posted: February 28, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Cardiac Dimensions Pty Ltd ( Cardiac Dimensions, Inc. ):
Functional Mitral Regurgitation
Percutaneous Mitral Valve Repair
Percutaneous Mitral Valve Annuloplasty
Coronary Sinus Annuloplasty
 Secondary Mitral Regurgitation
Functional MR
FMR
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Cardiovascular Diseases
Heart Diseases
Mitral Valve Insufficiency
Heart Valve Diseases